Treatment of an ulcerated hemangioma with recombinant platelet-derived growth factor.
Sugarman
Jeffrey L
JL
University of California, San Francisco, Department of Dermatology, Box 0316, San Francisco, CA 94143-0316, USA.
Mauro
Theodora M
TM
Frieden
Ilona J
IJ
D000287:Administration, Topical; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000077214:Becaplermin; D004359:Drug Therapy, Combination; D005260:Female; D005782:Gels; D005938:Glucocorticoids / Q000627:therapeutic use; D006391:Hemangioma / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007223:Infant; D008795:Metronidazole / Q000008:administration & dosage / Q000627:therapeutic use; D010982:Platelet-Derived Growth Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D011239:Prednisolone / Q000627:therapeutic use; D020574:Proto-Oncogene Proteins c-sis; D014456:Ulcer / Q000209:etiology* / Q000473:pathology
D000890:Anti-Infective Agents; D005782:Gels; D005938:Glucocorticoids; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D008795:Metronidazole; D000077214:Becaplermin; D011239:Prednisolone